Elesclomol

SKU: orb1301014

Description

Elesclomol is a lipophilic copper ionophore that induces oxidative stress and apoptosis in cancer cells. It is widely used in research to study copper-dependent cell death (cuproptosis) and has been shown to inhibit FDX1, disrupting iron-sulfur cluster biogenesis in both in vitro and in vivo models.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 488832-69-5
• MW: 400.52
• Purity: 99.51% (May vary between batches)
• Formula: C₁₉H₂₀N₄O₂S₂
• SMILES: CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1
• Target: Apoptosis,Cuproptosis,ROS,Reactive Oxygen Species,HSP
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:7.4 mg/mL (18.48 mM);2% DMSO+40% PEG300+5% Tween 80+ 53% Saline:5 mg/mL (12.48 mM);DMSO:250 mg/mL (624.19 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  MCF-7 cells:0.024 μM|Ramos cells:0.02 μM (EC50)|SK-MEL-5 cells:0.11 μM|HL-60 cells:9 nM
• In Vivo:
  Elesclomol exhibits significant inhibitory effects on the viability of SK-MEL-5, MCF-7, and HL-60 cells with IC50 values of 110, 24, and 9 nM, respectively. It induces the production of copper-dependent reactive oxygen species (ROS) and toxicity in yeast cells not by targeting specific intracellular sites but through interaction with the electron transport chain, which leads to elevated levels of ROS in organelles and consequently, cell death. Furthermore, treatment with 100 nM Elesclomol significantly induces the expression of heat shock response genes and metallothionein genes in Hs294T cells as analyzed through Affymetrix gene chip at 6 hours post-treatment. In Ramos Burkitt's lymphoma B cells treated with 100 nM Elesclomol, Hsp70 RNA levels increase by 4.8-fold and 160-fold after 1 and 6 hours, respectively. Additionally, ROS levels rise by 20% and 385% after 0.5 and 6 hours of treatment, with antioxidant pretreatments like N-acetylcysteine and Tiron inhibiting the induction of Hsp70. Treatment with 200 nM Elesclomol for 18 hours increases early and late apoptosis in HSB2 cells by 3.7 and 11 times, respectively, through the induction of oxidative stress.
• In Vitro:
  In nude mouse models carrying human breast cancer (MDA435, MCF7, and ZR-75-1), lung cancer (RER), or lymphoma (U937), Elesclomol ([25-100 mg/kg]) alone demonstrated no anticancer activity. However, it significantly enhanced the efficacy of chemotherapeutic agents such as paclitaxel, leading to tumor regression and extended lifespan in mice.
• Cell Research:
  Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.(Only for Reference)

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Menkes, inhibit, Elesclomol, Fe-S cluster, ferredoxin 1, FDX1, hereditary copper, HSP70, Inhibitor, Apoptosis, cancer, copper ionophore, copper, Cuproptosis, STA4783, STA-4783, STA 4783, ROS, ReactiveOxygenSpecies, Reactive Oxygen Species, oxidative stress, β5 strand, α2/α3 helices

Compound Identifiers

PubChem CID

300471